JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (4): 514-518.doi: 10.3969/j.issn.1674-8115.2021.04.016
• Clinical research • Previous Articles Next Articles
Jin-jun CAO(), Wei XIE, Xiao-dong ZHU, Hao XIA(
)
Received:
2020-07-13
Online:
2021-04-28
Published:
2021-05-14
Contact:
Hao XIA
E-mail:caojinjun037@163.com;xiahao@xinhuamed.com.cn
CLC Number:
Jin-jun CAO, Wei XIE, Xiao-dong ZHU, Hao XIA. Clinical analysis of Kaposi form hemangioendothelioma in 19 children[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(4): 514-518.
Characteristic | Without KMP (n=12) | With KMP (n=7) | P value |
---|---|---|---|
Gender/n (%) | 0.617 | ||
Male | 9 (75.0) | 4 (57.1) | |
Female | 3 (25.0) | 3 (42.9) | |
Onset age/n (%) | 0.547 | ||
Antenatal | 1 (8.3) | 0 (0) | |
At birth | 6 (50.0) | 5 (71.4) | |
<1 year | 3 (25.0) | 2 (28.6) | |
≥1 year | 2 (16.4) | 0 (0) | |
Location/n(%) | 0.165 | ||
Head and face | 5 (41.7) | 1 (14.3) | |
Trunk | 1 (8.3) | 3 (42.8) | |
Extremity | 6 (50.0) | 3 (42.8) | |
Operation/n(%) | 0.435 | ||
Completely removed | 6 (50.0) | 2 (28.6) | |
Partially excised | 2 (16.7) | 3 (42.8) | |
Biopsy | 4 (33.3) | 2 (28.6) | |
Prognosis/n(%) | 0.350 | ||
Cured | 7 (58.3) | 2 (28.6) | |
Survival with tumor | 5 (41.7) | 5 (71.4) |
Tab 1 Clinical data of children with KHE
Characteristic | Without KMP (n=12) | With KMP (n=7) | P value |
---|---|---|---|
Gender/n (%) | 0.617 | ||
Male | 9 (75.0) | 4 (57.1) | |
Female | 3 (25.0) | 3 (42.9) | |
Onset age/n (%) | 0.547 | ||
Antenatal | 1 (8.3) | 0 (0) | |
At birth | 6 (50.0) | 5 (71.4) | |
<1 year | 3 (25.0) | 2 (28.6) | |
≥1 year | 2 (16.4) | 0 (0) | |
Location/n(%) | 0.165 | ||
Head and face | 5 (41.7) | 1 (14.3) | |
Trunk | 1 (8.3) | 3 (42.8) | |
Extremity | 6 (50.0) | 3 (42.8) | |
Operation/n(%) | 0.435 | ||
Completely removed | 6 (50.0) | 2 (28.6) | |
Partially excised | 2 (16.7) | 3 (42.8) | |
Biopsy | 4 (33.3) | 2 (28.6) | |
Prognosis/n(%) | 0.350 | ||
Cured | 7 (58.3) | 2 (28.6) | |
Survival with tumor | 5 (41.7) | 5 (71.4) |
Lesion involvement | Without KMP (n=12) | With KMP (n=7) | P value |
---|---|---|---|
Skin/n (%) | 0.617 | ||
Yes | 9 (69.2) | 4 (30.8) | |
No | 3 (50.0) | 3 (50.0) | |
Deep muscle/n (%) | 0.017 | ||
Yes | 5 (41.7) | 7 (58.3) | |
No | 7 (100.0) | 0 (0) |
Tab 2 Relationship between KMP and tumor involvement sites
Lesion involvement | Without KMP (n=12) | With KMP (n=7) | P value |
---|---|---|---|
Skin/n (%) | 0.617 | ||
Yes | 9 (69.2) | 4 (30.8) | |
No | 3 (50.0) | 3 (50.0) | |
Deep muscle/n (%) | 0.017 | ||
Yes | 5 (41.7) | 7 (58.3) | |
No | 7 (100.0) | 0 (0) |
1 | Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis[J]. Am J Surg Pathol, 1993, 17(4): 321-328. |
2 | Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals[J]. J Pediatr, 2013, 162(1): 142-147. |
3 | Kelly M. Kasabach-Merritt phenomenon[J]. Pediatr Clin North Am, 2010, 57(5): 1085-1089. |
4 | 李冰, 张茜, 赵志华, 等. 新生儿卡波西型血管内皮瘤伴K-M现象一例[J]. 中华儿科杂志, 2015, 53(2): 144-145. |
5 | 高鹏飞, 舒曼, 谢钧韬, 等. 卡波西型血管内皮瘤13例临床分析[J]. 中华实用儿科临床杂志, 2017, 32(11): 841-844. |
6 | Drolet BA, Trenor CC, Brandão LR, et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma[J]. J Pediatr, 2013, 163(1): 285-291. |
7 | Ji Y, Yang K, Peng S, et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon[J]. Br J Dermatol, 2018, 179(2): 457-463. |
8 | Dasgupta R, Fishman SJ. ISSVA classification[J]. Semin Pediatr Surg, 2014, 23(4): 158-161. |
9 | Nakaya T, Morita K, Kurata A, et al. Multifocal Kaposiform hemangioendothelioma in multiple visceral organs: an autopsy of 9-day-old female baby[J]. Hum Pathol, 2014, 45(8): 1773-1777. |
10 | Ryu YJ, Choi YH, Cheon JE, et al. Imaging findings of Kaposiform hemangioendothelioma in children[J]. Eur J Radiol, 2017, 86: 198-205. |
11 | Fernández Y, Bernabeu-Wittel M, García-Morillo JS. Kaposiform hemangioendothelioma[J]. Eur J Intern Med, 2009, 20(2):106-113. |
12 | Gruman A, Liang MG, Mulliken JB, et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon[J]. J Am Acad Dermatol, 2005, 52(4): 616-622. |
13 | Duan L, Renzi S, Weidman D, et al. Sirolimustreatment of an infant with intrathoracic Kaposiform hemangioendothelioma complicated by life-threatening pleural and pericardial effusions[J]. J Pediatr Hematol Oncol, 2020, 42(1): 74-78. |
14 | Tlougan BE, Lee MT, Drolet BA, et al. Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey[J]. J Pediatr Hematol Oncol, 2013, 35(8): 618-622. |
15 | Chiu YE, Drolet BA, Blei F, et al. Variable response to propranolol treatment of Kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon[J]. Pediatr Blood Cancer, 2012, 59(5): 934-938. |
16 | Filippi L, Tamburini A, Berti E, et al. Successful propranolol treatment of a Kaposiform hemangioendothelioma apparently resistant to propranolol[J]. Pediatr Blood Cancer, 2016, 63(7): 1290-1292. |
17 | Jiang RS, Hu R. Successful treatment of Kasabach-Merritt syndrome arising from Kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery[J]. Int J Clin Oncol, 2012, 17(5): 512-516. |
18 | Liu XH, Li JY, Qu XH, et al. Clinical outcomes for systemic corticosteroids versus vincristine in treating Kaposiform hemangioendothelioma and tufted angioma[J]. Medicine (Baltimore), 2016, 95(20): e3431. |
19 | Ji Y, Chen SY, Xiang B, et al. Sirolimus for the treatment of progressive Kaposiform hemangioendothelioma: a multicenter retrospective study[J]. Int J Cancer, 2017, 141(4): 848-855. |
20 | George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas[J]. Arch Dermatol, 2004, 140(8): 963-969. |
21 | Fahrtash F, McCahon E, Arbuckle S. Successful treatment of Kaposiform hemangioendothelioma and tufted angioma with vincristine[J]. J Pediatr Hematol Oncol, 2010, 32(6): 506-510. |
22 | Peng SH, Yang KY, Xu ZC, et al. Vincristine and sirolimus in the treatment of Kaposiform haemangioendothelioma[J]. J Paediatr Child Health, 2019, 55(9): 1119-1124. |
23 | Hartman KR, Moncur JT, Minniti CP, et al. Mediastinal Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon [J]. J Pediatr Hematol, 2009, 31(9): 690-692. |
24 | Wang Z, Yao W, Sun H, et al. Sirolimus therapy for Kaposiform hemangioendothelioma with long-term follow-up[J]. J Dermatol, 2019, 46(11): 956-961. |
25 | Malhotra Y, Yang CS, McNamara J, et al. Congenital Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon successfully treated with low-dose radiation therapy[J]. Pediatr Dermatol, 2014, 31(5): 595-598. |
26 | Wang P, Zhou W, Tao L, et al. Clinical analysis of Kasabach-Merritt syndrome in 17 neonates[J]. BMC Pediatr, 2014, 14: 146. |
27 | Schaefer BA, Wang DH, Merrow AC, et al. Long-term outcome for Kaposiform hemangioendothelioma: a report of two cases[J]. Pediatr Blood Cancer, 2017, 64(2): 284-286. |
[1] | Jia-shi ZHU, Hong LI, Jing-bo SHAO, Na ZHANG, Jing-wei YANG, Kai CHEN, Zhen WANG, Hui JIANG. A clinical study on treatment failure of childhood acute lymphoblastic leukemia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 764-769. |
[2] | CHOI Yu-hsin, YANG Xin, WU Jian-yong. Causes of impacted maxillary incisors and progresses in orthodontic treatment [J]. , 2020, 40(4): 543-. |
[3] | RAN Shu-jun, LIANG Jing-ping. Aerosol transmission prevention of novel coronavirus in dental clinics [J]. , 2020, 40(3): 282-. |
[4] | QIAN Jie-lei, SHU Rong. Management on prevention of new coronavirus infection in periodontal treatment [J]. , 2020, 40(2): 145-. |
[5] | ZENG Ling-peng, ZHANG Qing, GUAN Yan-xing, LIU Shao-zheng, CHEN Qing-jie, ZHANG Qing. Diagnosis and surgical treatment of adult Merkel diverticulum with complications [J]. , 2020, 40(2): 242-. |
[6] | HU Zhe1*, FENG Qing1*, DENG Xue-qin1, HE Yan1, LI Ming-chun1, DONG Chen-jie2, HU Jing-fen3, ZHANG Nan3, GAO Yan4, CHU Shao-li1, YANG Hui1#, CHEN Xin1#. Hypertension control in Jiading, Shanghai and its relevant factors [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(12): 1652-1655. |
[7] | SHEN Cai, TENG Yin-cheng. Research progress in progesterone resistance mechanism and novel treatment of endometrial cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(12): 1677-1682. |
[8] | ZHANG Shi-yun, LAI Guang-yun, WANG Jun. Comparative study on the regeneration capacity of tissue in root canals between concentrated growth factor and blood clot [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(10): 1365-1370. |
[9] | ZHANG Feng-chun, ZHANG Shuo-yuan, CHEN Tian-en, XU Ying-chun. Clinical application of PD-1/PD-L1 to prognosis prediction and treatment of triple-negative breast cancer [J]. , 2020, 40(1): 128-. |
[10] | DONG Xiao-jing1, ZHANG Nan1, GAN Lu1, WU Yi-ying1, CHEN Yun-yun1, FANG Qiong2. Compliance analysis of adjuvant therapy in elderly patients with breast cancer under case-management model [J]. , 2019, 39(2): 170-. |
[11] | DU Zhe-yi1*, ZHANG Lei1*, ZHANG Jia-ting1, DU Jiang1, SHI Da-qing2, BAO Jia-yi1, WU Qian-ying1, ZHANG Jing-ying1, DONG Ping1. Investigation on alcohol among the patients with methadone maintenance treatment in Shanghai [J]. , 2019, 39(2): 193-. |
[12] | YUAN Yuan, MEI Jun. Effects and mechanisms of glutamic-pyruvic transaminase 2 on cisplatin resistance in gastric cancer [J]. , 2019, 39(10): 1134-. |
[13] | ZHANG Yi-qin1, XIE Song-ming2, WANG Wen-an1. Diagnosis and treatment of a case of pulmonary embolism with normal D-dimer [J]. , 2019, 39(1): 106-. |
[14] | GAO Tao, ZHU Xiao-zhong, BAO Bing-bo, LI Xing-wei, ZHENG Xian-you. Research progress of neurogenic bowel dysfunction in spinal cord injury [J]. , 2018, 38(9): 1116-. |
[15] | HONG Ting, XUE Xiao-mei, HE Bin. Research progress of endogenous exosomes as nano drug delivery system for treatment of myocardial ischemia [J]. , 2018, 38(8): 984-. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 589
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 810
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||